| |
|
|
|
Hyatt Regency Bethesda, Bethesda, MD
October 21-23, 2013
October 21, 2013: Generating Evidence for Reimbursement Decisions: Therapeutics - 8:15 Welcome Remarks from the Conference Director
- 8:20 Chairperson’s Opening Remarks
- 8:30 Real-World Data as a Tool for Establishing the Value of a Therapeutic
- 9:00 Joint Presentation: Utilizing EHRs in HEOR
- 10:00 Coffee Break
- 10:30 Towards a Continuous Learning Ecosystem: Data Innovations and Collaborations to Improve Clinical Outcomes and Reduce Cost of Care
- 11:00 Why Hasn’t Your Real-World Data Given You the Real-World Evidence?
- 11:30 Sponsored Presentation
- 12:00 pm The Value and Impact of Real World Data in Healthcare Decision Making: A Case Study
- 1:55 Chairperson’s Opening Remarks
- 2:00 Value-Based Pricing: Holy Grail or Fool’s Gold
- 2:30 Controlling the Cost of Cancer Drugs in Europe – HTA and the Case for a Fresh Start
- 3:00 What Are the Practical Drug Policies that Will Help Drive Down Health Care Spending and Improve Patient Outcomes?
- 3:30 Sponsored Presentation (Opportunity Available)
- 3:45 Refreshment Break in the Exhibit Hall
- 4:15 Case Study: Building a Global Value Dossier for a Novel Antibiotic and Differentiating a New Therapeutic Class
- 4:45 Panel Discussion: Integrating Payer’s Perspective into Product Development
- 5:15 Welcome Reception in Exhibit Hall for Both Tracks of the Summit
- 6:15 End of Day
October 22, 2013: Plenary Shared Session: Evidence-Based Reimbursement in Personalized Medicine/Companion Diagnostics - 8:00-8:20 am Morning Coffee
- 8:20 Chairperson’s Remarks
- 8:30 Generating Evidence for Reimbursement Decisions: Strategies and Tactics
- 9:00 Leaning In: Successful Strategies as a Manufacturer to Engage Payers in Diagnostic Technology Assessment and Coverage
- 9:30 Sponsored Presentation (Opportunity Available)
- 10:00 Coffee Break in the Exhibit Hall
- 10:30 Oncology Drug Development - Meeting The Evidentiary Needs of Various Stakeholders
- 11:30 Using Simulation Modeling to Generate Evidence for Reimbursement Discussions
- 11:45 Panel Discussion: Panel Discussion: Evidence-Based Reimbursement for Evidence-Based Personalized Medicine: Does Any of It Exist?
Generating Evidence for Reimbursement Decisions: Diagnostics - 1:55 Chairperson’s Remarks
- 2:00 Medicare Payment for Diagnostics, Speed Bumps or Road Blocks
- 2:30 Evaluating Novel Diagnostics for Reimbursement
- 3:00 Next Generation Sequencing vs. Individual Assays – Implications for Demonstrating Clinical Utility in the Context of Reimbursement Decisions
- 3:30 Refreshment Break in the Exhibit Hall
- 4:00 Reimbursement Reform for Advanced Personalized Diagnostic
- 4:30 Sponsored Presentation
- 5:00 Panel Discussion: Reimbursement of Molecular Diagnostics: Analysis and Forecast
October 23, 2013 Generating Evidence for Reimbursement Decisions: Diagnostics - 8:00 Problem Solving Breakout Discussions with Continental Breakfast
- 8:55 Chairperson’s Remarks
- 9:00 Demonstrating Clinical Utility Towards Commercialization of Proprietary Molecular Diagnostics
- 9:30 Beginning with the End in Mind: Planning to Address Payer Coverage Considerations
- 10:00 Automatable, Evidence-Based Prior Authorization for Gene Tests: A Reality Now
- 10:15 Sponsored Presentation
- 10:30 Coffee Break in the Exhibit Hall
- 11:00 Understanding the Value of Advanced Diagnostics: Aligning Labs, Clinicians and Payers to Make Better Decisions
- 11:30 Strategies for the Successful Launch of a Companion Diagnostic Test
- 12:55 Chairperson’s Remarks
- 1:00 CPT Codes for Multigene Testing Using Next-Generation Sequencing: Opportunities and Challenges Ahead
- 1:30 Development of the new AMA Molecular Pathology CPT Codes
- 2:00 Coverage Coding and Reimbursement in Advanced Molecular Diagnostics
- 2:30 Panel Discussion: What New Codes Mean for Various Diagnostics Stakeholders
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute |
|
|
Invited Speakers:
|
|
- Mark J. Cziraky, Pharm.D., Vice President, Industry Sponsored Research, HealthCore, Inc.
- Gregory Hess, M.D., CMO, Global Health Economics & Outcomes Research, IMS Health
- Vipul Kashyap, Director, Information Management & Analytics, Cigna Healthcare
- Hui Cao, M.D., Ph.D., Senior Director, Personalized Healthcare, R&D Information, AstraZeneca
- Russell Knoth, Ph.D., Director, US Health Economics & Outcomes Research, Eisai, Inc.
- J. Jaime Caro, MDCM, FRCPC, FACP, Senior Vice President, Health Economics, United BioSource Corporation
- Christian Elze, Senior Partner, Catenion
- Robert Popovian, Pharm.D., MS, Senior Director, Advocacy and Professional Relations, US Public Affairs, Pfizer, Inc.
- Carl Foster, Executive Vice President, Business Development, Cempra Pharmaceuticals
- Josephine Sollano, Dr.P.H., Vice President, Health Economics and Outcomes Research and Medical Communications, Oncology Business Unit, Pfizer Inc.
- Laura Housman, Vice President, Global Market Access, Pricing and HE&OR, Novartis Molecular Diagnostics
- Roy D. Baynes, M.D., Ph.D., Senior Vice President, Oncology Therapeutics, Gilead Sciences, Inc.
- Jerry Conway, Vice President, Reimbursement & Payer Strategy, Foundation Medicine, Inc.
- Badri Rengarajan, M.D., Medical Director, Archimedes, Inc.
- John Warren, Senior Director, Health Policy, McDermott Will & Emery
- Elaine K. Jeter, M.D., J1 MolDx Medical Director, Palmetto GBA
- Brian Gorin, Managing Principal, Analysis Group, Inc.
- Mark Erwin, Senior Director, Reimbursement & Government Affairs, Prometheus Therapeutics & Diagnostics
- Catherine Schnabel, Ph.D., Vice President, Medical, Clinical & Regulatory Affairs, bioTheranostics, Inc.
- Pam Baker, Senior Director, Market Access & Policy, CardioDx, Inc.
- Lynn Feldman, MBA, CEO, SimulConsult
- Matthew Zubiller, Vice President, Decision Management, McKesson Health Solutions
- John R. Ridge, Director, Global Reimbursement and Healthcare Economics, Ventana Medical Systems, a member of the Roche Group
- Roger Klein, M.D., J.D., Department of Molecular Pathology, Cleveland Clinic Foundation
- Victoria Pratt, Ph.D., FACMG, Director, Pharmacogenetics Laboratory, Indiana University School of Medicine
- Danielle Scelfo, Director, Government Affairs, Genomic Health
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|